WCN26-7232 EFFECTS OF CANAGLIFLOZIN ON BETA-CELL FUNCTION AND INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS: DATA FROM THE CANVAS TRIAL

Read full text Summarise with VIRAT
Authors: HC Arthur Tang, Emily K. Yeung, Amanda N. Siriwardana, Luke Buizen, Sydney C.W. Tang, Min Jun, Sradha S. Kotwal, Clare Arnott, David Z.I. Cherney, Bruce Charles Neal, Vlado Perkovic, Hiddo JL Heerspink
+1 more Brendon Lange Neuen
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycaemic control in those with established type 2 diabetes and reduce the incidence of new onset diabetes in those without it. The homeostatic model assessment of insulin resistance (HOMA-IR) is a validated measure of insulin resistance, while the proinsulin-to-C-peptide (PIC) ratio serves as a surrogate marker of β-cell function. We evaluated the effects of the SGLT2 inhibitor canagliflozin on insulin resistance and β-cell function, as assessed by HOMA-IR and PIC ratio, in patients with type 2 diabetes and high risk of atherosclerotic cardiovascular disease.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Management and Research Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104640–104640
Publication date
25 March 2026
Language
EN